AstraZeneca plc (NYSE:AZN) declared a semi-annual dividend on Friday, July 31st, Wall Street Journal reports. Stockholders of record on Friday, August 14th will be paid a dividend of 0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th.
AstraZeneca has a dividend payout ratio of 93.0% indicating that its dividend is currently covered by earnings, but may not be in the future if the company’s earnings decline. Equities analysts expect AstraZeneca to earn $2.63 per share next year, which means the company should continue to be able to cover its $1.86 annual dividend with an expected future payout ratio of 70.7%.
Shares of NYSE:AZN opened at $55.78 on Friday. The stock’s 50-day moving average price is $54.53 and its 200-day moving average price is $50.30. AstraZeneca has a 12-month low of $36.15 and a 12-month high of $64.94. The stock has a market capitalization of $151.93 billion, a P/E ratio of 29.54, a price-to-earnings-growth ratio of 1.71 and a beta of 0.55. The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 1.32.
AstraZeneca (NYSE:AZN) last posted its earnings results on Thursday, July 30th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.04. The company had revenue of $6.28 billion for the quarter, compared to analysts’ expectations of $6.27 billion. AstraZeneca had a return on equity of 37.83% and a net margin of 8.36%. AstraZeneca’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $0.73 earnings per share. As a group, research analysts predict that AstraZeneca will post 2.04 EPS for the current year.
Several analysts recently issued reports on AZN shares. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research note on Friday, May 29th. FIG Partners started coverage on AstraZeneca in a research note on Thursday, April 23rd. They issued a “reduce” rating on the stock. Zacks Investment Research cut AstraZeneca from a “buy” rating to a “hold” rating and set a $59.00 target price on the stock. in a research note on Wednesday. Oddo Bhf cut AstraZeneca from a “buy” rating to a “reduce” rating in a research report on Wednesday, June 24th. Finally, Cowen lifted their price objective on AstraZeneca from $55.00 to $60.00 in a research report on Wednesday, June 10th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and a consensus price target of $61.00.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.